Acute Porphyria Drug Database

L04AB01 - Etanercept
Propably not porphyrinogenic
PNP

Important Information
Patients on drug therapy causing immunosuppression have an increased risk of infections. Since infections have a potential to trigger acute porphyric attacks vigilance is motivated regarding signs or symptoms of infection and/or possible symptoms of a porphyric attack
Side effects
Infections are common in patients using immunosuppressants and since infections might trigger an acute porphyric attack, vigilance regarding signs and symptoms of an infection and/ or a porphyric attack is recommended.
Rationale
Etanercept is not metabolized by cytochrome P450 enzymes. No pharmacokinetic porphyrinogenic effects are suspected.
Chemical description
Etanercept is a recombinant form of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) fused to the Fc fragment of human immunoglobulin G1 (IgG1).
Therapeutic characteristics
Etanercept is a biologic response modifier used in the treatment of moderately to severely active rheumatoid arthritis and active and progressive psoriatic arthritis. It is administered by subcutaneous injection.
Metabolism and pharmacokinetics
Since etanercept is a fusion glycoprotein, consisting entirely of human protein components, it is expected to undergo proteolysis. Hence studies were not conducted. The cytochrome P450 system and other commonly used metabolic pathways are not involved in the metabolism of etanercept, so there is little potential of metabolic drug interactions. In clinical trials, no interactions have been observed when Enbrel was administered with glucocorticoids, salicylates (except sulfasalazine), nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics, or methotrexate.

References

  1. Drug reference publications
  2. McEvoy GK, editor. Etanercept. The AHFS Drug Information 2008. Bethesda, MD: American Society of Health-System Pharmacists; 2009. Electronic version (31.09.10). #2287
  3. Sweetman SC, editor. Martindale: The complete drug reference. Etanercept. Pharmaceutical Press 2009. #2288
  4. Government bodies
  5. European Public Assessment Report, Enbrel (Scientific discussion).European Medicines Agency (EMEA). Accessible from: emea.europa.eu #2286
  6. Summary of Product Characteristics
  7. The electronic Medicines Compendium (eMC). Enbrel. Summary of Product Characteristics (SPC). updated September 2014. #2289

Similar drugs
Explore alternative drugs in similar therapeutic classes L04A / L04AB or go back.

 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙